Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and sponsoring an awareness campaign in one of its priority therapeutic areas.
Sponsoring initiatives in January, Glaucoma Awareness Month, has become an annual tradition for Bausch + Lomb. In 2024 and 2025, the eye health company, which sells multiple glaucoma treatments, partnered with the Glaucoma Research Foundation (GRF) to run the “Faces of Glaucoma” campaign. The campaign told patients’ stories to show how glaucoma affects people of various ages, genders and races.
This year, Bausch + Lomb is again working with the GRF on a fundraising challenge. The company will match every dollar the nonprofit raises during January, up to $20,000, to support glaucoma research, according to a Monday announcement.
Bausch + Lomb is also marking the awareness month by sponsoring The Glaucoma Foundation’s social media campaign. Throughout January, TGF is highlighting glaucoma patients and advocates to raise awareness of the disease and its impact. TGF will use personal stories to stress the importance of early glaucoma detection.
Glaucoma is a chronic, progressive condition that can lead to vision loss, and Bausch + Lomb is among the companies working to improve outcomes for those with the disease.
The company paid $99 million upfront to acquire Elios Vision in 2024. Elios developed a minimally invasive glaucoma surgery procedure using an excimer laser that Bausch + Lomb has predicted could generate peak sales of $175 million.
The company is also working to expand its portfolio of glaucoma medicines including, Vyzulta. Bausch + Lomb’s next big hope is BL1107, an alpha-2B agonist that the company believes can improve on existing glaucoma eye drops such as brimonidine and timolol. A phase 2 trial linked BL1107 to vision gains, spurring Bausch + Lomb to advance an asset it sees as the future standard of care.